TABLE 2.

A selected list of studies that used PRS using: (1) extrapolation method from disease variants, or (2) direct pharmacogenomics variants of drug response.

Study	Disease/trait	Medication/medication class	Outcome measure (e.g., treatment stratification, response, dose)	Method	Number of variants, if reported	Ancestry of patients in the study	Prediction metrics (e.g., R 2), if reported
PRS Extrapolated from disease or trait GWAS
Natarajan et al. 32	Atherosclerosis/coronary artery disease	Statin	Treatment stratification (i.e., risk reduction with statin versus placebo per PRS strata)	Risk allele counting weighed by effect size	57	European	NA
Oni‐orisan et al. 33	Coronary heart disease	Statin	Risk reduction with statin versus nonstatin per PRS strata	Risk allele counting weighed by effect size	164	European and African American	NA
Kappel et al. 37	Schizophrenia	Clozapine	Clozapine dose	Bayesian regression and continuous shrinkage 20		European	32%
Guo et al. 38	Schizophrenia	Antipsychotics	Treatment response (reduction of PANSS)	Clumping + thresholding (PRSice‐2 68 )		Han Chinese	48% for both clinical and PRS
PRS constructed from pharmacogenomic variants
Lanfear et al. 41	Heart failure	β‐blockers	Survival benefit (β‐blockers*PRS interaction)	Risk allele counting weighed by effect size	44	European	NA
Pardiñas et al. 48	Schizophrenia	Clozapine	Clozapine metabolic ratio	Clumping + thresholding (PRSice‐2 68 )	8	Multi‐ancestry (European, African+Asian)	7.2%
Amare AT et al. 49	Bipolar	Lithium	Lithium response	Bayesian regression and continuous shrinkage 20		European	2.6%
De Pieri et al. 50	Schizophrenia, bipolar	Antipsychotics	Treatment response	Clumping + thresholding (PRSice‐2 68 )	11	European	PPV:64%, NPV:57%, sensitivity 63%, Specificity: 58%